Adamas Pharmaceuticals, Inc.
Adamas Pharmaceuticals, Inc. ADMS Peers
See (ADMS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ADMS | $8.22 | N/A | N/A | N/A | N/A | N/A |
| ZTS | $161.46 | -1.34% | 71.88B | 29.52 | $5.47 | +1.15% |
| HLN | $11.10 | +0.68% | 50.04B | 26.42 | $0.42 | +1.52% |
| TAK | $14.32 | +0.32% | 45.05B | 62.24 | $0.23 | +4.11% |
| TEVA | $16.57 | -1.25% | 18.99B | -14.41 | -$1.15 | N/A |
| ITCI | $131.87 | N/A | 14.05B | -180.64 | -$0.73 | N/A |
| RDY | $14.33 | -1.21% | 11.93B | 18.13 | $0.79 | +0.67% |
| NBIX | $120.56 | -1.95% | 11.93B | 40.87 | $2.95 | N/A |
| CTLT | $63.48 | N/A | 11.52B | -27.84 | -$2.28 | N/A |
| VTRS | $8.48 | -4.50% | 9.95B | -2.67 | -$3.18 | +5.61% |
Stock Comparison
ADMS vs ZTS Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ZTS has a market cap of 71.88B. Regarding current trading prices, ADMS is priced at $8.22, while ZTS trades at $161.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZTS's P/E ratio is 29.52. In terms of profitability, ADMS's ROE is +2.26%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, ADMS is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs HLN Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, HLN has a market cap of 50.04B. Regarding current trading prices, ADMS is priced at $8.22, while HLN trades at $11.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HLN's P/E ratio is 26.42. In terms of profitability, ADMS's ROE is +2.26%, compared to HLN's ROE of +0.09%. Regarding short-term risk, ADMS is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs TAK Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TAK has a market cap of 45.05B. Regarding current trading prices, ADMS is priced at $8.22, while TAK trades at $14.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TAK's P/E ratio is 62.24. In terms of profitability, ADMS's ROE is +2.26%, compared to TAK's ROE of +0.04%. Regarding short-term risk, ADMS is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs TEVA Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TEVA has a market cap of 18.99B. Regarding current trading prices, ADMS is priced at $8.22, while TEVA trades at $16.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TEVA's P/E ratio is -14.41. In terms of profitability, ADMS's ROE is +2.26%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, ADMS is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ITCI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ITCI has a market cap of 14.05B. Regarding current trading prices, ADMS is priced at $8.22, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ADMS's ROE is +2.26%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, ADMS is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs RDY Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, RDY has a market cap of 11.93B. Regarding current trading prices, ADMS is priced at $8.22, while RDY trades at $14.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas RDY's P/E ratio is 18.13. In terms of profitability, ADMS's ROE is +2.26%, compared to RDY's ROE of +0.18%. Regarding short-term risk, ADMS is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs NBIX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, NBIX has a market cap of 11.93B. Regarding current trading prices, ADMS is priced at $8.22, while NBIX trades at $120.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 40.87. In terms of profitability, ADMS's ROE is +2.26%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, ADMS is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs CTLT Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, CTLT has a market cap of 11.52B. Regarding current trading prices, ADMS is priced at $8.22, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ADMS's ROE is +2.26%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, ADMS is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs VTRS Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, VTRS has a market cap of 9.95B. Regarding current trading prices, ADMS is priced at $8.22, while VTRS trades at $8.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas VTRS's P/E ratio is -2.67. In terms of profitability, ADMS's ROE is +2.26%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, ADMS is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ELAN Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ELAN has a market cap of 6.27B. Regarding current trading prices, ADMS is priced at $8.22, while ELAN trades at $12.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ELAN's P/E ratio is 16.83. In terms of profitability, ADMS's ROE is +2.26%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, ADMS is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs RGC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, RGC has a market cap of 5.40B. Regarding current trading prices, ADMS is priced at $8.22, while RGC trades at $415.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas RGC's P/E ratio is -1185.71. In terms of profitability, ADMS's ROE is +2.26%, compared to RGC's ROE of -0.25%. Regarding short-term risk, ADMS is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs LNTH Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, LNTH has a market cap of 5.20B. Regarding current trading prices, ADMS is priced at $8.22, while LNTH trades at $75.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LNTH's P/E ratio is 21.40. In terms of profitability, ADMS's ROE is +2.26%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ADMS is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs PRGO Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, PRGO has a market cap of 3.70B. Regarding current trading prices, ADMS is priced at $8.22, while PRGO trades at $26.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PRGO's P/E ratio is -22.43. In terms of profitability, ADMS's ROE is +2.26%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, ADMS is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs AMRX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, AMRX has a market cap of 3.38B. Regarding current trading prices, ADMS is priced at $8.22, while AMRX trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AMRX's P/E ratio is -181.75. In terms of profitability, ADMS's ROE is +2.26%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, ADMS is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ALVOW Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ALVOW has a market cap of 3.31B. Regarding current trading prices, ADMS is priced at $8.22, while ALVOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ALVOW's P/E ratio is N/A. In terms of profitability, ADMS's ROE is +2.26%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, ADMS is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ALVO Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ALVO has a market cap of 3.07B. Regarding current trading prices, ADMS is priced at $8.22, while ALVO trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ALVO's P/E ratio is -12.39. In terms of profitability, ADMS's ROE is +2.26%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, ADMS is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs HCM Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, HCM has a market cap of 2.33B. Regarding current trading prices, ADMS is priced at $8.22, while HCM trades at $13.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HCM's P/E ratio is 66.10. In terms of profitability, ADMS's ROE is +2.26%, compared to HCM's ROE of +0.05%. Regarding short-term risk, ADMS is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs DCPH Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, DCPH has a market cap of 2.21B. Regarding current trading prices, ADMS is priced at $8.22, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ADMS's ROE is +2.26%, compared to DCPH's ROE of -0.52%. Regarding short-term risk, ADMS is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs EMBCV Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, EMBCV has a market cap of 1.91B. Regarding current trading prices, ADMS is priced at $8.22, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ADMS's ROE is +2.26%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, ADMS is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SUPN Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SUPN has a market cap of 1.83B. Regarding current trading prices, ADMS is priced at $8.22, while SUPN trades at $32.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SUPN's P/E ratio is 24.72. In terms of profitability, ADMS's ROE is +2.26%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, ADMS is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs BGM Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, BGM has a market cap of 1.79B. Regarding current trading prices, ADMS is priced at $8.22, while BGM trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BGM's P/E ratio is -61.50. In terms of profitability, ADMS's ROE is +2.26%, compared to BGM's ROE of -0.03%. Regarding short-term risk, ADMS is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs BHC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, BHC has a market cap of 1.65B. Regarding current trading prices, ADMS is priced at $8.22, while BHC trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BHC's P/E ratio is -37.25. In terms of profitability, ADMS's ROE is +2.26%, compared to BHC's ROE of +0.05%. Regarding short-term risk, ADMS is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs TARO Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TARO has a market cap of 1.62B. Regarding current trading prices, ADMS is priced at $8.22, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TARO's P/E ratio is 30.05. In terms of profitability, ADMS's ROE is +2.26%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ADMS is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs EVO Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, EVO has a market cap of 1.42B. Regarding current trading prices, ADMS is priced at $8.22, while EVO trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EVO's P/E ratio is -6.17. In terms of profitability, ADMS's ROE is +2.26%, compared to EVO's ROE of -0.22%. Regarding short-term risk, ADMS is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs INDV Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, INDV has a market cap of 1.41B. Regarding current trading prices, ADMS is priced at $8.22, while INDV trades at $11.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas INDV's P/E ratio is -225.80. In terms of profitability, ADMS's ROE is +2.26%, compared to INDV's ROE of -0.01%. Regarding short-term risk, ADMS is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ANIP Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ANIP has a market cap of 1.28B. Regarding current trading prices, ADMS is priced at $8.22, while ANIP trades at $59.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ANIP's P/E ratio is -50.07. In terms of profitability, ADMS's ROE is +2.26%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, ADMS is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs PCRX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, PCRX has a market cap of 1.21B. Regarding current trading prices, ADMS is priced at $8.22, while PCRX trades at $26.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PCRX's P/E ratio is -11.67. In terms of profitability, ADMS's ROE is +2.26%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, ADMS is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs DVAX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, DVAX has a market cap of 1.19B. Regarding current trading prices, ADMS is priced at $8.22, while DVAX trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DVAX's P/E ratio is -19.80. In terms of profitability, ADMS's ROE is +2.26%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ADMS is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs AMPH Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, AMPH has a market cap of 1.14B. Regarding current trading prices, ADMS is priced at $8.22, while AMPH trades at $24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AMPH's P/E ratio is 8.75. In terms of profitability, ADMS's ROE is +2.26%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, ADMS is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs HROW Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, HROW has a market cap of 980.98M. Regarding current trading prices, ADMS is priced at $8.22, while HROW trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HROW's P/E ratio is -43.82. In terms of profitability, ADMS's ROE is +2.26%, compared to HROW's ROE of -0.36%. Regarding short-term risk, ADMS is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs COLL Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, COLL has a market cap of 947.23M. Regarding current trading prices, ADMS is priced at $8.22, while COLL trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas COLL's P/E ratio is 24.16. In terms of profitability, ADMS's ROE is +2.26%, compared to COLL's ROE of +0.19%. Regarding short-term risk, ADMS is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs PAHC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, PAHC has a market cap of 942.41M. Regarding current trading prices, ADMS is priced at $8.22, while PAHC trades at $23.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PAHC's P/E ratio is 29.81. In terms of profitability, ADMS's ROE is +2.26%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, ADMS is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs PETQ Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, PETQ has a market cap of 919.17M. Regarding current trading prices, ADMS is priced at $8.22, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ADMS's ROE is +2.26%, compared to PETQ's ROE of +0.06%. Regarding short-term risk, ADMS is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs AVDL Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, AVDL has a market cap of 885.16M. Regarding current trading prices, ADMS is priced at $8.22, while AVDL trades at $9.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AVDL's P/E ratio is -17.94. In terms of profitability, ADMS's ROE is +2.26%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, ADMS is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs CRON Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, CRON has a market cap of 797.82M. Regarding current trading prices, ADMS is priced at $8.22, while CRON trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CRON's P/E ratio is 14.79. In terms of profitability, ADMS's ROE is +2.26%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ADMS is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs EMBC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, EMBC has a market cap of 722.06M. Regarding current trading prices, ADMS is priced at $8.22, while EMBC trades at $12.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EMBC's P/E ratio is 13.88. In terms of profitability, ADMS's ROE is +2.26%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, ADMS is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs EOLS Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, EOLS has a market cap of 618.32M. Regarding current trading prices, ADMS is priced at $8.22, while EOLS trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EOLS's P/E ratio is -10.78. In terms of profitability, ADMS's ROE is +2.26%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, ADMS is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs BDSI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, BDSI has a market cap of 577.05M. Regarding current trading prices, ADMS is priced at $8.22, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ADMS's ROE is +2.26%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ADMS is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs TLRY Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TLRY has a market cap of 443.95M. Regarding current trading prices, ADMS is priced at $8.22, while TLRY trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TLRY's P/E ratio is -0.39. In terms of profitability, ADMS's ROE is +2.26%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, ADMS is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SIGA Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SIGA has a market cap of 437.93M. Regarding current trading prices, ADMS is priced at $8.22, while SIGA trades at $6.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SIGA's P/E ratio is 9.15. In terms of profitability, ADMS's ROE is +2.26%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, ADMS is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ZYBT Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ZYBT has a market cap of 421.31M. Regarding current trading prices, ADMS is priced at $8.22, while ZYBT trades at $8.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZYBT's P/E ratio is 148.17. In terms of profitability, ADMS's ROE is +2.26%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, ADMS is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs KMDA Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, KMDA has a market cap of 392.76M. Regarding current trading prices, ADMS is priced at $8.22, while KMDA trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas KMDA's P/E ratio is 24.39. In terms of profitability, ADMS's ROE is +2.26%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, ADMS is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ORGO Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ORGO has a market cap of 381.83M. Regarding current trading prices, ADMS is priced at $8.22, while ORGO trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ORGO's P/E ratio is -18.81. In terms of profitability, ADMS's ROE is +2.26%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, ADMS is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs EBS Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, EBS has a market cap of 349.01M. Regarding current trading prices, ADMS is priced at $8.22, while EBS trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EBS's P/E ratio is -2.49. In terms of profitability, ADMS's ROE is +2.26%, compared to EBS's ROE of -0.27%. Regarding short-term risk, ADMS is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs TKNO Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TKNO has a market cap of 347.37M. Regarding current trading prices, ADMS is priced at $8.22, while TKNO trades at $6.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TKNO's P/E ratio is -14.13. In terms of profitability, ADMS's ROE is +2.26%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, ADMS is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SNDL Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SNDL has a market cap of 337.06M. Regarding current trading prices, ADMS is priced at $8.22, while SNDL trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SNDL's P/E ratio is -5.24. In terms of profitability, ADMS's ROE is +2.26%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, ADMS is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs CGC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, CGC has a market cap of 324.15M. Regarding current trading prices, ADMS is priced at $8.22, while CGC trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CGC's P/E ratio is -0.50. In terms of profitability, ADMS's ROE is +2.26%, compared to CGC's ROE of -0.88%. Regarding short-term risk, ADMS is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ALIM Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ALIM has a market cap of 301.29M. Regarding current trading prices, ADMS is priced at $8.22, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ADMS's ROE is +2.26%, compared to ALIM's ROE of -0.34%. Regarding short-term risk, ADMS is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs ACB Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ACB has a market cap of 286.50M. Regarding current trading prices, ADMS is priced at $8.22, while ACB trades at $5.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ACB's P/E ratio is 27.47. In terms of profitability, ADMS's ROE is +2.26%, compared to ACB's ROE of -0.06%. Regarding short-term risk, ADMS is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs LNDC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, LNDC has a market cap of 263.63M. Regarding current trading prices, ADMS is priced at $8.22, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ADMS's ROE is +2.26%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, ADMS is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs LFCR Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, LFCR has a market cap of 238.81M. Regarding current trading prices, ADMS is priced at $8.22, while LFCR trades at $6.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LFCR's P/E ratio is -4.39. In terms of profitability, ADMS's ROE is +2.26%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, ADMS is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs TYHT Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TYHT has a market cap of 229.17M. Regarding current trading prices, ADMS is priced at $8.22, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ADMS's ROE is +2.26%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, ADMS is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs AQST Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, AQST has a market cap of 225.47M. Regarding current trading prices, ADMS is priced at $8.22, while AQST trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AQST's P/E ratio is -3.91. In terms of profitability, ADMS's ROE is +2.26%, compared to AQST's ROE of +1.07%. Regarding short-term risk, ADMS is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs OGI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, OGI has a market cap of 179.34M. Regarding current trading prices, ADMS is priced at $8.22, while OGI trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas OGI's P/E ratio is 10.31. In terms of profitability, ADMS's ROE is +2.26%, compared to OGI's ROE of +0.05%. Regarding short-term risk, ADMS is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs REPH Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, REPH has a market cap of 177.42M. Regarding current trading prices, ADMS is priced at $8.22, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas REPH's P/E ratio is -8.04. In terms of profitability, ADMS's ROE is +2.26%, compared to REPH's ROE of -0.15%. Regarding short-term risk, ADMS is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ESPR Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ESPR has a market cap of 169.06M. Regarding current trading prices, ADMS is priced at $8.22, while ESPR trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ESPR's P/E ratio is -1.00. In terms of profitability, ADMS's ROE is +2.26%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, ADMS is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs DERM Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, DERM has a market cap of 157.95M. Regarding current trading prices, ADMS is priced at $8.22, while DERM trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DERM's P/E ratio is -10.12. In terms of profitability, ADMS's ROE is +2.26%, compared to DERM's ROE of -0.52%. Regarding short-term risk, ADMS is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs BIOA Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, BIOA has a market cap of 139.82M. Regarding current trading prices, ADMS is priced at $8.22, while BIOA trades at $3.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BIOA's P/E ratio is -1.97. In terms of profitability, ADMS's ROE is +2.26%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, ADMS is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs THTX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, THTX has a market cap of 117.25M. Regarding current trading prices, ADMS is priced at $8.22, while THTX trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas THTX's P/E ratio is -36.43. In terms of profitability, ADMS's ROE is +2.26%, compared to THTX's ROE of +0.16%. Regarding short-term risk, ADMS is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SCTL Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SCTL has a market cap of 116.13M. Regarding current trading prices, ADMS is priced at $8.22, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ADMS's ROE is +2.26%, compared to SCTL's ROE of -0.15%. Regarding short-term risk, ADMS is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs PROC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, PROC has a market cap of 113.95M. Regarding current trading prices, ADMS is priced at $8.22, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PROC's P/E ratio is 1.53. In terms of profitability, ADMS's ROE is +2.26%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ADMS is less volatile compared to PROC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs OPTN Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, OPTN has a market cap of 97.22M. Regarding current trading prices, ADMS is priced at $8.22, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ADMS's ROE is +2.26%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, ADMS is less volatile compared to OPTN. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ZOM Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ZOM has a market cap of 95.35M. Regarding current trading prices, ADMS is priced at $8.22, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ADMS's ROE is +2.26%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, ADMS is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs IRWD Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, IRWD has a market cap of 95.31M. Regarding current trading prices, ADMS is priced at $8.22, while IRWD trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas IRWD's P/E ratio is -3.10. In terms of profitability, ADMS's ROE is +2.26%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, ADMS is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs GRVI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, GRVI has a market cap of 88.91M. Regarding current trading prices, ADMS is priced at $8.22, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ADMS's ROE is +2.26%, compared to GRVI's ROE of -5.25%. Regarding short-term risk, ADMS is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs CRDL Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, CRDL has a market cap of 87.59M. Regarding current trading prices, ADMS is priced at $8.22, while CRDL trades at $1.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CRDL's P/E ratio is -3.12. In terms of profitability, ADMS's ROE is +2.26%, compared to CRDL's ROE of -2.08%. Regarding short-term risk, ADMS is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs CPIX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, CPIX has a market cap of 74.21M. Regarding current trading prices, ADMS is priced at $8.22, while CPIX trades at $4.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CPIX's P/E ratio is -20.67. In terms of profitability, ADMS's ROE is +2.26%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, ADMS is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs INCR Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, INCR has a market cap of 74.05M. Regarding current trading prices, ADMS is priced at $8.22, while INCR trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas INCR's P/E ratio is -3.92. In terms of profitability, ADMS's ROE is +2.26%, compared to INCR's ROE of -0.07%. Regarding short-term risk, ADMS is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ZYNE Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ZYNE has a market cap of 70.12M. Regarding current trading prices, ADMS is priced at $8.22, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ADMS's ROE is +2.26%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ADMS is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SSIC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SSIC has a market cap of 66.72M. Regarding current trading prices, ADMS is priced at $8.22, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ADMS's ROE is +2.26%, compared to SSIC's ROE of +0.03%. Regarding short-term risk, ADMS is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ASRT Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ASRT has a market cap of 65.69M. Regarding current trading prices, ADMS is priced at $8.22, while ASRT trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ASRT's P/E ratio is -2.14. In terms of profitability, ADMS's ROE is +2.26%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, ADMS is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs VLNS Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, VLNS has a market cap of 61.46M. Regarding current trading prices, ADMS is priced at $8.22, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ADMS's ROE is +2.26%, compared to VLNS's ROE of N/A. Regarding short-term risk, ADMS is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs JUPW Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, JUPW has a market cap of 49.33M. Regarding current trading prices, ADMS is priced at $8.22, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ADMS's ROE is +2.26%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, ADMS is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs QLI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, QLI has a market cap of 38.68M. Regarding current trading prices, ADMS is priced at $8.22, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas QLI's P/E ratio is -4.92. In terms of profitability, ADMS's ROE is +2.26%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ADMS is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs RMTI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, RMTI has a market cap of 34.03M. Regarding current trading prices, ADMS is priced at $8.22, while RMTI trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas RMTI's P/E ratio is -99.57. In terms of profitability, ADMS's ROE is +2.26%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, ADMS is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs HEXO Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, HEXO has a market cap of 31.24M. Regarding current trading prices, ADMS is priced at $8.22, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ADMS's ROE is +2.26%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ADMS is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SCYX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SCYX has a market cap of 30.08M. Regarding current trading prices, ADMS is priced at $8.22, while SCYX trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.75. In terms of profitability, ADMS's ROE is +2.26%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, ADMS is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs QNTM Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, QNTM has a market cap of 28.29M. Regarding current trading prices, ADMS is priced at $8.22, while QNTM trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas QNTM's P/E ratio is -0.93. In terms of profitability, ADMS's ROE is +2.26%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, ADMS is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SXTC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SXTC has a market cap of 26.61M. Regarding current trading prices, ADMS is priced at $8.22, while SXTC trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SXTC's P/E ratio is 0.01. In terms of profitability, ADMS's ROE is +2.26%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, ADMS is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs KALA Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, KALA has a market cap of 24.33M. Regarding current trading prices, ADMS is priced at $8.22, while KALA trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas KALA's P/E ratio is -0.51. In terms of profitability, ADMS's ROE is +2.26%, compared to KALA's ROE of -3.69%. Regarding short-term risk, ADMS is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs CYTH Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, CYTH has a market cap of 23.59M. Regarding current trading prices, ADMS is priced at $8.22, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ADMS's ROE is +2.26%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, ADMS is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs EGRX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, EGRX has a market cap of 19.44M. Regarding current trading prices, ADMS is priced at $8.22, while EGRX trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas EGRX's P/E ratio is 1.76. In terms of profitability, ADMS's ROE is +2.26%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, ADMS is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for ADMS.
ADMS vs DRRX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, DRRX has a market cap of 18.27M. Regarding current trading prices, ADMS is priced at $8.22, while DRRX trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas DRRX's P/E ratio is -1.23. In terms of profitability, ADMS's ROE is +2.26%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, ADMS is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs GELS Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, GELS has a market cap of 17.18M. Regarding current trading prices, ADMS is priced at $8.22, while GELS trades at $1.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas GELS's P/E ratio is -7.58. In terms of profitability, ADMS's ROE is +2.26%, compared to GELS's ROE of -0.21%. Regarding short-term risk, ADMS is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs TXMD Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TXMD has a market cap of 16.90M. Regarding current trading prices, ADMS is priced at $8.22, while TXMD trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TXMD's P/E ratio is -7.68. In terms of profitability, ADMS's ROE is +2.26%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, ADMS is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs SISI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, SISI has a market cap of 15.17M. Regarding current trading prices, ADMS is priced at $8.22, while SISI trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas SISI's P/E ratio is N/A. In terms of profitability, ADMS's ROE is +2.26%, compared to SISI's ROE of -1.41%. Regarding short-term risk, ADMS is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ACRX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ACRX has a market cap of 14.58M. Regarding current trading prices, ADMS is priced at $8.22, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ADMS's ROE is +2.26%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, ADMS is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs FLGC Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, FLGC has a market cap of 14.22M. Regarding current trading prices, ADMS is priced at $8.22, while FLGC trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas FLGC's P/E ratio is -0.48. In terms of profitability, ADMS's ROE is +2.26%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, ADMS is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs COSM Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, COSM has a market cap of 13.54M. Regarding current trading prices, ADMS is priced at $8.22, while COSM trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.40. In terms of profitability, ADMS's ROE is +2.26%, compared to COSM's ROE of -0.51%. Regarding short-term risk, ADMS is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs AYTU Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, AYTU has a market cap of 12.53M. Regarding current trading prices, ADMS is priced at $8.22, while AYTU trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AYTU's P/E ratio is -1.36. In terms of profitability, ADMS's ROE is +2.26%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, ADMS is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs PRPH Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, PRPH has a market cap of 12.02M. Regarding current trading prices, ADMS is priced at $8.22, while PRPH trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is -0.13. In terms of profitability, ADMS's ROE is +2.26%, compared to PRPH's ROE of -1.59%. Regarding short-term risk, ADMS is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs AGRX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, AGRX has a market cap of 10.43M. Regarding current trading prices, ADMS is priced at $8.22, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ADMS's ROE is +2.26%, compared to AGRX's ROE of +1.04%. Regarding short-term risk, ADMS is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs TLPH Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, TLPH has a market cap of 10.38M. Regarding current trading prices, ADMS is priced at $8.22, while TLPH trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas TLPH's P/E ratio is -1.15. In terms of profitability, ADMS's ROE is +2.26%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, ADMS is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs NLTX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, NLTX has a market cap of 8.20M. Regarding current trading prices, ADMS is priced at $8.22, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ADMS's ROE is +2.26%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, ADMS is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs YCBD Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, YCBD has a market cap of 7.97M. Regarding current trading prices, ADMS is priced at $8.22, while YCBD trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas YCBD's P/E ratio is 0.01. In terms of profitability, ADMS's ROE is +2.26%, compared to YCBD's ROE of -8.81%. Regarding short-term risk, ADMS is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs LCI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, LCI has a market cap of 7.38M. Regarding current trading prices, ADMS is priced at $8.22, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas LCI's P/E ratio is -0.04. In terms of profitability, ADMS's ROE is +2.26%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ADMS is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs CPHI Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, CPHI has a market cap of 7.34M. Regarding current trading prices, ADMS is priced at $8.22, while CPHI trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas CPHI's P/E ratio is -1.01. In terms of profitability, ADMS's ROE is +2.26%, compared to CPHI's ROE of -0.45%. Regarding short-term risk, ADMS is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs BGXX Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, BGXX has a market cap of 7.26M. Regarding current trading prices, ADMS is priced at $8.22, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas BGXX's P/E ratio is -0.76. In terms of profitability, ADMS's ROE is +2.26%, compared to BGXX's ROE of -0.88%. Regarding short-term risk, ADMS is less volatile compared to BGXX. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.
ADMS vs ADMP Comparison
ADMS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ADMS stands at N/A. In comparison, ADMP has a market cap of 7.25M. Regarding current trading prices, ADMS is priced at $8.22, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ADMS currently has a P/E ratio of N/A, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ADMS's ROE is +2.26%, compared to ADMP's ROE of +0.00%. Regarding short-term risk, ADMS is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for ADMS.